Sector
PharmaceuticalsOpen
₹110.85Prev. Close
₹108.44Turnover(Lac.)
₹48.79Day's High
₹110.96Day's Low
₹108.5152 Week's High
₹132.4552 Week's Low
₹90.8Book Value
₹90.29Face Value
₹10Mkt Cap (₹ Cr.)
173.98P/E
0EPS
0Divi. Yield
09 Jul 2024
12:00 AM
Board Meeting
Agenda : Audited Result
18 Sep 2023
12:00 AM
AGM
Announcement Date: 18 Sep, 2023
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 15.83 | 15.83 | 15.83 | 15.83 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 136.13 | 134.73 | 114.96 | 88.11 |
Net Worth | 151.96 | 150.56 | 130.79 | 103.94 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 380.14 | 282.35 | 279.37 | 302.88 |
yoy growth (%) | 34.63 | 1.06 | -7.76 | 2.66 |
Raw materials | -251.78 | -195.34 | -163.36 | -197.47 |
As % of sales | 66.23 | 69.18 | 58.47 | 65.19 |
Employee costs | -29.87 | -26.04 | -22.98 | -19.07 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 39.51 | 6.25 | 29.34 | 31.18 |
Depreciation | -9.17 | -8.21 | -6.56 | -5 |
Tax paid | -11.54 | 2 | -9.45 | -8.9 |
Working capital | 27.78 | -24.07 | 15.15 | -3.81 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 34.63 | 1.06 | -7.76 | 2.66 |
Op profit growth | 124.95 | -49.44 | 2.07 | 22.36 |
EBIT growth | 193.24 | -59.49 | -0.21 | 23.74 |
Net profit growth | 238.93 | -58.5 | -10.7 | 38.93 |
| Particulars (Rupees in Crores.) | Mar-2024 |
|---|---|
Gross Sales | 367.35 |
Excise Duty | 0 |
Net Sales | 367.35 |
Other Operating Income | 1.24 |
Other Income | 0.1 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,665.8 | 130.91 | 3,99,537.26 | 867.6 | 0.81 | 5,536.99 | 98.75 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,205.8 | 35.29 | 1,21,311.57 | 1,405.2 | 0.25 | 3,172.6 | 156.19 |
Cipla Ltd CIPLA | 1,500.05 | 32.61 | 1,21,119.62 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Divis Laboratories Ltd DIVISLAB | 4,547 | 76.67 | 1,20,781.57 | 531 | 0.66 | 2,259 | 507.93 |
Dr Reddys Laboratories Ltd DRREDDY | 6,853.2 | 26.69 | 1,14,348.41 | 1,034.8 | 0.58 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Govardhan M Dhoot
Whole-time Director
Brijmohan Dhoot
Independent Director
Rukmesh P. Dhandhania
Independent Director
Nidhi S. Mundada
Independent Director
Praveen Saxena
Company Sec. & Compli. Officer
Jayant Barde
Director
Rakesh K. Milwani
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Mangalam Drugs and Organics Ltd
Summary
Mangalam Drugs and Organics Ltd was formerly incorporated on April 18, 1972 as a private limited company with the name Advent Pharma Pvt Ltd. On July 1, 1997, the Company changed their name from Advent Pharma Pvt Ltd to Mangalam Drugs and Organics Pvt Ltd. Thereafter, the Company converted into a Public Limited Company and name of the Company was changed from Advent Pharma Ltd to Mangalam Drugs and Organics Ltd on August 10, 2001. The company was promoted by Dhoot family. The company was established with a view to set up a plant for manufacture of organic and inorganic chemicals.The company is engaged in the manufacturing of chemicals, such as active pharma ingredients (API) perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates. The company has their manufacturing facilities at Vapi in Gujarat and Sangamner in Maharashtra. They also have an in-house Research and Development (R&D) Base. Their products include chloroquine phosphate I.P., aluminum chloride anhydrous, and dyes and intermediaries.In April 1, 1996 three other group companies, namely Mangalam Organics Pvt Ltd, Shree Mangalam Pharma Pvt Ltd and Mangalam Rasayan Pvt Ltd were amalgamated with the company. In the year 1999, the company launched a new product namely, Nimesulide. In the year 2001, they launched two new products namely Amodiaquine Hydrochloride and Amodiaquine. In the year 2003-2004, the bulk drug production capacity of the Company was increased from 350 MTPA to 600 MTPA. During th
Read More
What is the Mangalam Drugs and Organics Ltd share price today?
The Mangalam Drugs and Organics Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹109.92 today.
What is the Market Cap of Mangalam Drugs and Organics Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Mangalam Drugs and Organics Ltd is ₹173.98 Cr. as of 26 Jul ‘24
What is the PE and PB ratio of Mangalam Drugs and Organics Ltd?
The PE and PB ratios of Mangalam Drugs and Organics Ltd is 0 and 1.21 as of 26 Jul ‘24
What is the 52 Week High and Low of Mangalam Drugs and Organics Ltd?
The 52-week high/low is the highest and lowest price at which a Mangalam Drugs and Organics Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Mangalam Drugs and Organics Ltd is ₹90.8 and ₹132.45 as of 26 Jul ‘24
What is the CAGR of Mangalam Drugs and Organics Ltd?
Mangalam Drugs and Organics Ltd's CAGR for 5 Years at 27.37%, 3 Years at -16.83%, 1 Year at 2.50%, 6 Month at 7.15%, 3 Month at 7.63% and 1 Month at 1.48%.
What is the shareholding pattern of Mangalam Drugs and Organics Ltd?
The shareholding pattern of Mangalam Drugs and Organics Ltd is as follows:
Promoters - 50.32 %
Institutions - 0.21 %
Public - 49.47 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
